Intra-Cellular Therapies Appoints Mark Neumann as Executive Vice President, Chief Commercial Officer
16 October 2018 - 11:00PM
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a
biopharmaceutical company focused on the development of
therapeutics for central nervous system (CNS) disorders, today
announced the appointment of Mark Neumann as Executive
Vice President, Chief Commercial Officer. Mr. Neumann
has over 30 years of biopharmaceutical industry experience with a
strong track record of building high-performing commercial teams
and successfully executing numerous product launches across a range
of therapeutic areas including specialty and primary care
businesses.
Mr. Neumann joins ITCI from Amgen where he was initially
recruited as Vice President, Marketing to build and establish a new
U.S. cardiovascular business unit, and launch Amgen’s first ever
cardiovascular medicines. In his most recent role as Vice
President, Global Marketing with leadership of nephrology,
inflammation, and bone health, Mr. Neumann was responsible for
conceiving therapeutic area strategies, developing marketing
platforms for global launches and directing commercial assessments
for external business development opportunities.
Prior to Amgen, Mr. Neumann spent 25 years at Bristol-Myers
Squibb (BMS) and held senior U.S. and global commercial roles in
neuroscience, cardiovascular and diabetes. During his tenure
at BMS he led sales and marketing for the U.S. neuroscience
business unit, and delivered strong growth of the antipsychotic
Abilify. He also held the position of Vice President, Global
Commercialization for neuroscience where he established a new
worldwide disease area strategy and directed the commercialization
of neuroscience pipeline assets. Mark received his Bachelor
of Arts in Economics and Business Administration degree from
Lafayette College.
“Mark is a proven leader with broad experience developing and
implementing commercial strategies for early and late-stage assets
within neuroscience and cardiovascular therapeutic fields. We
believe his expertise further strengthens and complements our
growing organization as we prepare for the commercialization of
lumateperone and further advance our pipeline,” said
Dr. Sharon Mates, Chairman and CEO of Intra-Cellular
Therapies.
"I am very excited to join the leadership team at Intra-Cellular
Therapies and look forward to leading the commercial
organization as we advance the launch preparations for lumateperone
as well as developing commercial strategies for the Company’s
pipeline,” said Mr. Neumann.
About Intra-Cellular Therapies
Intra-Cellular Therapies is developing novel drugs for the
treatment of neuropsychiatric and neurodegenerative diseases,
including Parkinson's disease and Alzheimer's disease. The Company
is developing its lead drug candidate, lumateperone (also known as
ITI-007), for the treatment of schizophrenia, bipolar disorder,
behavioral disturbances in patients with Alzheimer's disease,
depression, and other neuropsychiatric and neurological disorders.
The Company is also utilizing its phosphodiesterase (PDE) platform
and other proprietary chemistry platforms to develop drugs for the
treatment of CNS and other disorders. The lead molecule in the
Company's PDE1 portfolio, ITI-214, is in development for the
treatment of Parkinson's disease and heart failure.
INVESTORS:
Intra-Cellular Therapies, Inc. Juan Sanchez, M.D. Vice
President, Corporate Communications and Investor Relations
646-440-9333
Burns McClellan, Inc. Lisa Burns agray@burnsmc.com
212-213-0006
MEDIA INQUIRIES:Patrick Ryan, Esq.Corporate Media Relations, WCG
Worldpryan@wcgworld.com
Intra Cellular Therapies (NASDAQ:ITCI)
Historical Stock Chart
From Apr 2024 to May 2024
Intra Cellular Therapies (NASDAQ:ITCI)
Historical Stock Chart
From May 2023 to May 2024